TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28728038

Group type: EXPERIMENTAL
Intervention: Smoking cessation group treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Predictors of engagement
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Full multivariable logistic regression model
Number of subjects: 178
Study: 25978378

Group type: EXPERIMENTAL
Intervention: Sound of running water (SRW) played by a mobile application
Number of subjects: 18

Group type: COMPARATOR
Intervention: No sound of running water (without SRW)
Number of subjects: 18
Study: 23273106

Group type: EXPERIMENTAL
Intervention: delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 0
Study: 21654553

Group type: EXPERIMENTAL
Intervention: Interactive case-based module
Number of subjects: 43

Group type: COMPARATOR
Intervention: Traditional textbook-style module
Number of subjects: 43
Study: 18635335

Group type: EXPERIMENTAL
Intervention: Endovascular repair using the Powerlink endovascular graft
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 258
Study: 16234990

Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 5 l of saline
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 3 l of saline
Number of subjects: 142

Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 142
Study: 12973821

Group type: EXPERIMENTAL
Intervention: Salurin (Julphar, UAE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lasix (Hoechst AG, Germany)
Number of subjects: 24
Study: 10993032

Group type: EXPERIMENTAL
Intervention: Tibolone (n = 32)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens plus sequential norgestrel (CEEP) (n = 31)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No treatment control (n = 50)
Number of subjects: 113
Study: 9298264

Group type: EXPERIMENTAL
Intervention: Who Do You Tell program (N = 117)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Wait-list control condition (N = 114)
Number of subjects: 231
Study: 7504880

Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg/day (n = 115)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 to 200 mg/day (n = 130)
Number of subjects: 368

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (n = 123)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 368
Study: 3517508

Group type: EXPERIMENTAL
Intervention: Nifedipine (200 micrograms/L)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30551120

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation
Number of subjects: 70
Study: 29665432

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise (MCE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Seated rest condition (Control)
Number of subjects: 18
Study: 27307415

Group type: EXPERIMENTAL
Intervention: High-intensity atorvastatin (80 mg/d before PCI and 40 mg/d thereafter for 1 year)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Moderate-intensity atorvastatin (20 mg/d for 1 year)
Number of subjects: 798
Study: 24709487

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m², IV) + Vandetanib (100 mg daily, PO)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m², IV)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Vandetanib (D → V)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Crossover Vandetanib response
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Crossover Vandetanib (D → V)
Number of subjects: 131
Study: 22680916

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve analgesia (CFA), ropivacaine 25 mg bolus and 5 mg/h infusion for 24 hours after surgery.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral analgesics (control group).
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve analgesia (CFA).
Number of subjects: 62
Study: 20228403

Group type: EXPERIMENTAL
Intervention: Valsartan (up to 160 mg daily)
Number of subjects: 9306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study: 17655723

Group type: EXPERIMENTAL
Intervention: Bulkamid (hydrogel cross‐linked with polyacrylamide)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Permacol (porcine dermal collagen)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1-week bowel diary and SF-36 forms
Number of subjects: 10
Study: 15953083

Group type: EXPERIMENTAL
Intervention: Moisturizing cream applied twice daily for 6 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control site (left leg, no treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moisturizing cream
Number of subjects: 17
Study: 12745799

Group type: EXPERIMENTAL
Intervention: 5‐min period of ischemic preconditioning before cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional normothermic retrograde blood cardioplegia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 10578982

Group type: EXPERIMENTAL
Intervention: Endoscopic cytology
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Antitubercular treatment
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 228
Study: 9772616

Group type: EXPERIMENTAL
Intervention: Xilixin granule (XLXG) combined with radiotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Zhenqi Fuzheng granule combined with radiotherapy
Number of subjects: 36
Study: 8340983

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/d as calcium citrate malate)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 3729636

Group type: EXPERIMENTAL
Intervention: Usual oxygen prescriptions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room air (through nasal prongs)
Number of subjects: 12
Study: 31256309

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 12 cmH2O (P12)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 15 cmH2O (P15)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 20 cmH2O (P20)
Number of subjects: 75
Study: 29877615

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Both RFA and SBRT
Number of subjects: 440
Study: 26742708

Group type: EXPERIMENTAL
Intervention: (131)I‐MIBG (444 or 666 MBq/kg) plus arsenic trioxide (0.15 or 0.25 mg/m(2))
Number of subjects: 21

Group type: COMPARATOR
Intervention: (131)I‐MIBG alone (historical data)
Number of subjects: 21
Study: 25899875

Group type: EXPERIMENTAL
Intervention: Photon irradiation (25 × 2Gy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Electron beam irradiation (13 × 3Gy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Comparison of photon vs electron irradiation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall treatment efficacy
Number of subjects: 72
Study: 22516569

Group type: EXPERIMENTAL
Intervention: Milch technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stimson technique
Number of subjects: 60
Study: 20861520

Group type: EXPERIMENTAL
Intervention: Conventional facemask (CM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Respiratory snorkel (RS)
Number of subjects: 10
Study: 18165839

Group type: EXPERIMENTAL
Intervention: Cognitive Performance Scale value (CPS) superior to 3 (impaired)
Number of subjects: 4010

Group type: COMPARATOR
Intervention: Scoring more than 3 on the CPS (disabled)
Number of subjects: 4010

Group type: EXPERIMENTAL
Intervention: Less than one meal/day, reduced appetite, malnutrition, reduced social activity, experiencing a flare-up of a recurrent or chronic problem, and hospitalisation
Number of subjects: 4010
Study: 16415699

Group type: EXPERIMENTAL
Intervention: Sertraline (maximum dose of 200 mg/d)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 328
Study: 12556405

Group type: EXPERIMENTAL
Intervention: BQ-123 (ET(A) receptor antagonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin converting enzyme inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10096581

Group type: EXPERIMENTAL
Intervention: Tat toxoid
Number of subjects: 5
Study: 7852062

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Written intervention
Number of subjects: 255

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 255
Study: 2639596

Group type: EXPERIMENTAL
Intervention: FIBS preparation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Typical treatment for uveitis
Number of subjects: 60
Study: 956557

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0
Study: 29801187

Group type: EXPERIMENTAL
Intervention: Work-Related Medical Rehabilitation (WMR)
Number of subjects: 476
Study: 28494646

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Supportive care and chemotherapeutics (control)
Number of subjects: 182
Study: 25638793

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: HAMD17
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Evans6 and Toronto7 subscales
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Subscales (general)
Number of subjects: 210
Study: 23433061

Group type: EXPERIMENTAL
Intervention: e‐learning course for health promoters
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 280
Study: 21647703

Group type: EXPERIMENTAL
Intervention: Pan-retinal photocoagulation (PRP)
Number of subjects: 29
Study: 19808388

Group type: EXPERIMENTAL
Intervention: RFA of RA CFAEs
Number of subjects: 85

Group type: COMPARATOR
Intervention: No RFA of RA CFAEs
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: After LA RFA
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: After final procedure
Number of subjects: 85
Study: 16794458

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (including 4'-O-methyl-epicatechin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 15609769

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol (100 microg/50 microg)
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Fluticasone propionate (100 microg)
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Montelukast (10 mg)
Number of subjects: 1910
Study: 11140385

Group type: EXPERIMENTAL
Intervention: Earrings with a surface layer consisting of 24-carat gold
Number of subjects: 60

Group type: COMPARATOR
Intervention: Earrings with a surface layer of titanium nitride
Number of subjects: 60
Study: 9286518

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution dripped onto enamel blocks from 0 to 8 times/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoride-free dentifrice used by all subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Water fluoridated at 0.70 ppm F
Number of subjects: 12
Study: 7950179

Group type: EXPERIMENTAL
Intervention: Jiangzhi Zhongyao Pian (JZZYP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3313776

Group type: EXPERIMENTAL
Intervention: Mesalazine (5-ASA) suppositories (3 x 250 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29439307

Group type: EXPERIMENTAL
Intervention: UltraTENS
Number of subjects: 61

Group type: COMPARATOR
Intervention: PhP
Number of subjects: 61
Study: 28811158

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral therapy (DAAs)
Number of subjects: 89
Study: 26256135

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 46
Study: 24205185

Group type: EXPERIMENTAL
Intervention: MVA.HIVA vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: EPI vaccines
Number of subjects: 48
Study: 21128879

Group type: EXPERIMENTAL
Intervention: dalcetrapib 600 mg/day
Number of subjects: 476

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 476
Study: 18370982

Group type: EXPERIMENTAL
Intervention: Nebulized racemic albuterol
Number of subjects: 703

Group type: COMPARATOR
Intervention: Nebulized racemic epinephrine
Number of subjects: 703
Study: 16983056

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 13
Study: 12728413

Group type: EXPERIMENTAL
Intervention: Predonated autologous blood
Number of subjects: 83

Group type: COMPARATOR
Intervention: Postoperative unwashed blood salvage
Number of subjects: 83
Study: 11044422

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8698945

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hypnosis (Control)
Number of subjects: 0
Study: 1353514

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) bladder irrigation before catheter removal
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (no PVP-I irrigation)
Number of subjects: 264
Study: 6614059

Group type: EXPERIMENTAL
Intervention: New residences designed to be more normalizing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older institutional buildings designed for more custodial care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social aspects of normalizing environments
Number of subjects: 0
Study: 29713889

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 25
Study: 28689915

Group type: EXPERIMENTAL
Intervention: Vita Enamic
Number of subjects: 93

Group type: COMPARATOR
Intervention: Vitablocs Mark II
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 27119918

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (20 units)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA (60 units)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (20 units)
Number of subjects: 73
Study: 24560063

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS) tertiles (SS<7, 7 to 12, and >12)
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS)
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Patients who developed AKI
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS) tertiles
Number of subjects: 2268
Study: 21665116

Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization (RS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive stretching (PS)
Number of subjects: 14
Study: 19573482

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 to 160 mg/day, administered b.i.d.
Number of subjects: 62
Study: 16979126

Group type: EXPERIMENTAL
Intervention: Horse gram lectin (Dolichos biflorus agglutinin) skin prick test (SPT) at 100 microg/mL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DBA-specific IgE detection by ELISA and dot-blot
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Histamine release (HR) assay using leukocytes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Basophil HR by DBA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Identification of food allergy to horse gram
Number of subjects: 48
Study: 15219008

Group type: EXPERIMENTAL
Intervention: Oropharyngeal vancomycin (0.5 g of a 4% gel at 6-hour intervals)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (selective decontamination protocol including polymyxin E, tobramycin, and amphotericin B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oropharyngeal vancomycin
Number of subjects: 84
Study: 10931808

Group type: EXPERIMENTAL
Intervention: Remnant-like lipoprotein particles (RLPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total triglyceride-rich lipoproteins (TGLs) and LDL
Number of subjects: 0
Study: 9328328

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment with IFN‐alpha2b (3 million units 3 times weekly for 12 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 8222928

Group type: EXPERIMENTAL
Intervention: Dacron bifurcation prostheses (with or without velours or gelatin impregnation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double velours prostheses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dacron bifurcation prostheses (with gelatin impregnation)
Number of subjects: 100
Study: 3759279

Group type: EXPERIMENTAL
Intervention: Euphylong (E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Uniphyllin (U)
Number of subjects: 12
Study: 4913623

Group type: EXPERIMENTAL
Intervention: Maximal doses of histamine acid phosphate
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Supramaximal doses of histamine acid phosphate
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Maximal doses of pentagastrin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Supramaximal doses of pentagastrin
Number of subjects: 1
Study: 31732851

Group type: EXPERIMENTAL
Intervention: Grape juice (10 ml/kg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo drink (10 ml/kg/day)
Number of subjects: 14
Study: 31234919

Group type: EXPERIMENTAL
Intervention: Tong‐luo Qu‐tong plaster administered externally for 14 days (two courses, once daily)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Qi‐zheng Xiao‐tong plaster administered externally for 14 days (two courses, once daily)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both groups will document adverse events related to clinical symptoms and signs and results of laboratory tests during the clinical trials.
Number of subjects: 2000
Study: 28081543

Group type: EXPERIMENTAL
Intervention: Irinotecan/S‐1 (IRIS) therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: S‐1 monotherapy
Number of subjects: 127
Study: 25244676

Group type: EXPERIMENTAL
Intervention: Subclinical OC sample (HOC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low OC symptoms control sample (LOC)
Number of subjects: 52
Study: 23769807

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine plus normal saline solution
Number of subjects: 399

Group type: COMPARATOR
Intervention: Normal saline solution only
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Less than 1 L intravenous fluids
Number of subjects: 399

Group type: COMPARATOR
Intervention: Greater than 1 L intravenous fluids
Number of subjects: 399
Study: 21668768

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oxytocin (5 IU)
Number of subjects: 56
Study: 19837206

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (MT) + Cognitive Behavior Therapy (CBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Multidisciplinary treatment (MT)
Number of subjects: 83
Study: 16721304

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Advice from a physiotherapist
Number of subjects: 286
Study: 14699021

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.3125 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg and 0.3125 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 11407293

Group type: EXPERIMENTAL
Intervention: Rocuronium-thiopental (Ro-Th) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiopental-rocuronium (Th-Ro) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopental-succinylcholine (Th-Sx) group
Number of subjects: 90
Study: 9209015

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents (specific agents not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8315422

Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg/m2 on days 1 and 8 (every 3 weeks) with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group A)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Epirubicin administered only on day 1 with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group B)
Number of subjects: 141
Study: 2893637

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 0
Study: 29343468

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin-A (BoNT-A) injections (200 units: 60 into each masseter and 40 into each temporalis)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 23
Study: 27414159

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 24714351

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 80 mg elemental iron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (iron deficient)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (iron sufficient)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 60 mg and 80 mg elemental iron
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (iron deficient) and Placebo (iron sufficient)
Number of subjects: 32
Study: 22433756

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: FU/LV
Number of subjects: 0
Study: 19484401

Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation treatment (diode laser)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical fluoride treatment (protective varnish)
Number of subjects: 30